KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Thermo Fisher Scientific (TMO) EBT (2016 - 2025)

Thermo Fisher Scientific (TMO) has disclosed EBT for 16 consecutive years, with $1.9 billion as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, EBT rose 11.55% year-over-year to $1.9 billion, compared with a TTM value of $7.0 billion through Dec 2024, up 11.73%, and an annual FY2025 reading of $7.3 billion, up 3.85% over the prior year.
  • EBT was $1.9 billion for Q4 2024 at Thermo Fisher Scientific, up from $1.7 billion in the prior quarter.
  • Across five years, EBT topped out at $2.9 billion in Q4 2020 and bottomed at $828.0 million in Q1 2020.
  • Average EBT over 5 years is $1.9 billion, with a median of $1.8 billion recorded in 2022.
  • The sharpest move saw EBT surged 232.49% in 2021, then crashed 46.34% in 2023.
  • Year by year, EBT stood at $2.9 billion in 2020, then tumbled by 35.73% to $1.9 billion in 2021, then dropped by 4.56% to $1.8 billion in 2022, then dropped by 2.08% to $1.7 billion in 2023, then rose by 11.55% to $1.9 billion in 2024.
  • Business Quant data shows EBT for TMO at $1.9 billion in Q4 2024, $1.7 billion in Q3 2024, and $1.8 billion in Q2 2024.